Aktis Oncology, Inc. (AKTS)
NASDAQ:AKTS
[225Ac]Ac-Aky-1189, [64Cu]Cu-Aky-1189
Non Small Cell Lung Cancer, Head And Neck Cancer, Colorectal Adenocarcinoma, Triple Negative Breast Cancer (Tnbc), Cervical Adenocarcinoma, Urothelial Carcinoma Bladder, Hormone Receptor Positive Breast Adenocarcinoma
Phase I
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
May 28, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Aktis Oncology, Inc. (AKTS) have in its pipeline
AKTS is currently developing the following drugs: [225Ac]Ac-Aky-1189, [64Cu]Cu-Aky-1189. These drug candidates are in various stages of clinical development as the company works toward FDA approval.